Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-65 years of age, any ethnic group, either sex~2. Diagnostic and Statistical Manual, 4th edition (DSM IV) diagnosis of schizophrenia or schizoaffective disorder~3. Ability to participate fully in the informed consent process, or have a legal guardian able to participate in the informed consent process.~4. Patient cohort enriched for moderate to severe cognitive symptoms (composite Brief Assessment of Cognition in Schizophrenia (BACS) score 0-3 SD below the mean).~5. No change in antipsychotic for 8 weeks or longer. No change in antipsychotic dose for 4 weeks or longer.~6. No change in anticholinergic, benzodiazepine, or mood stabilizer medications for 4 weeks or longer.~7. No anticipated need to alter any of the above medications (antipsychotics, anticholinergics, benzodiazepines, or mood stabilizers) for the 10-week duration of the study.~Exclusion Criteria:~1. Unstable medical illness or neurologic illness (seizures, cerebrovascular accident); history of prostate, breast, uterine, or ovarian cancer.~2. Use of oral contraceptives or other hormonal supplementation such as estrogen.~3. Other concomitant medications for medical conditions will be addressed on a case-by-case base to determine if exclusionary.~4. Active expression of suicidal or homicidal ideation.~5. Comorbid substance dependence (other than nicotine dependence), or presenting symptoms likely substance-induced, as judged by a study physician.~6. Female patients who are pregnant or breast-feeding.~7. Known allergy to study medication.~8. Drugs with a narrow therapeutic index (e.g. thioridazine, mesoridazine, ziprasidone, clozapine, etc) will be excluded as suggested by the Federal Drug Administration (FDA); patients taking these agents will not be eligible for this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Pregnenolone
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).